Clarify the Role of Ongentys and Kynmobi for Parkinson's Disease

December 2020

Ongentys (opicapone) and Kynmobi (apomorphine) will add to the growing list of new meds for Parkinson's disease.

They're for "off" episodes...when symptoms (tremor, etc) return between carbidopa/levodopa doses, especially as Parkinson's progresses.

Recommend optimizing carbidopa/levodopa first...such as with more frequent dosing. Put the role of the new meds in perspective.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote